A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

December 31, 2007

Conditions
Transfusional Iron Overload
Interventions
DRUG

ICL670

Trial Locations (18)

10021

New York Presbyterian Hospital/Weill Medical College of Cornell University, New York

11215

New York Methodist Hospital, New York

11432

Queens Hospital Center, Jamaica

45229

Cincinnatti Children's Hospital Medical center, Cincinnatti

77030

Novartis Investigative Site, Houston

92868

Children's Hospital of Orange County, Orange

94609

Children's Hospital and Research Center - Oakland, Oakland

02115

Children's Hospital Boston, Boston

Unknown

Novartis investigative Site, Athens

Novartis Investigative Site, Ancona

Novartis Investigative Site, Brindisi

Novartis Investigative Site, Cagliari

Novartis Investigative Site, Cosenza

Novartis Investigative Site, Florence

Novartis Investigative Site, Milan

Novartis Investigative Site, Modena

Novartis Investigative Site, Napoli

Novartis Investigative Site, Torino

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY